Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of polysialic acid. The antibodies of the present technology are useful in methods for detecting and treating a polysialic acid-associated cancer in a subject in need thereof.

Abstract: Various embodiments are disclosed for providing machine learning routines with peripheral device data to infer driver activity and location. Peripheral device data may be collected on a peripheral device having a machine learning routine executing thereon to infer driver activity and perform improved estimation of driver location. Using driver activity and location estimation, contextually relevant delivery workflow assistance may be automatically provided to a delivery driver or other individual without requiring manual input, thereby improving driver safety and operational efficiency.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., multi-specific antibodies or antigen binding fragments thereof) that can bind to the GPA33 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a GPA33-associated cancer in a subject in need thereof.

Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Abstract: Provided herein are compositions comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and an anti-DOTA C825 antigen binding fragment. The engineered immune cells of the present technology are configured to bind to DOTA haptens that may be complexed with a diagnostic radiopharmaceutical (e.g., 111In). Also disclosed herein are methods for determining the in vivo biodistribution, viability, and expansion of the engineered immune cells described herein.

Abstract: The present disclosure provides kits and methods for tracking or monitoring in vivo biodistribution, viability, and/or expansion of immune cells in a cancer patient undergoing cellular immunotherapy.

Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Abstract: Provided herein are compositions, methods, and uses involving (i) bispecific binding agents that specifically bind to a cancer antigen, (ii) clearing agents, and (iii) radiotherapeutic agents for treating cancer. Also provided herein are uses and methods for treating HER2-related cancers.

Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: A method of manufacturing a remediation material uses a biogenic material as a substrate and involves preparing the surface of the substrate to enable a chemical reaction, and performing template-driven surface derivatization on the substrate to provide a net positive charge on the substrate. The remediation material may be placed into contact with surface water, ground water, soil, or sediment by at least one of a permeable reactive barrier, direct well injection, or direct introduction of the remediation material into soil or sediment, to remove contaminants from the surface water, ground water, soil, or sediment.

Abstract: The disclosure concerns methods and compositions for prevention of soil erosion, soil contamination and increased seed germination for agricultural products. Certain methods relate to coating seeds to withstand drought conditions. Other methods relate to soil compositions containing a biopolymer to withstand drought conditions or to prevent erosion, to control dust or to prevent contaminated soil erosion.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

Abstract: Compositions containing three and four-carbon acids labeled with 18F at the 2-position and to their use for emission tomography are disclosed.

Abstract: A method of manufacturing a remediation material is disclosed. The method includes providing a biogentic material as a substrate, preparing the surface of the substrate for a chemical reaction, and performing template-driven surface derivitization on the surface of the substrate to provide a net positive charge on the surface of the substrate. The remediation material may be placed into contact with surface water, ground water, soil, or sediment by at least one of a permeable reactive barrier, direct well injection, or direct introduction of the remediation material into soil or sediment, to remove contaminants from the surface water, ground water, soil, or sediment.

Abstract: A method providing a self-dispensing additive for buffering a projectile trapping medium and passivating spent projectiles trapped therein. The additive is a buffering compound formed as blocks of low-density foamed-concrete that self-dispenses the additive when contacted by the fired projectiles. The blocks contain dry components that may include one or more of low-solubility phosphate compounds, low-solubility aluminum compounds, iron compounds, sulfate compounds, and calcium carbonate mixed with a cementing material, water, and an aqueous-based foam in substantially stoichiometric amounts. The aqueous-based foam is added in a quantity sufficient to adjust the density of the block to neutral buoyancy in the projectile-trapping medium. The additive chemically stabilizes the medium while also passivating projectiles, in particular heavy-metal projectiles, trapped in the medium.